Cases & Deals

Invus participates in €20 million investment in Sensorion

Clients Invus

Jones Day advised Invus, as lead investor, alongside with Sofinnova, in the €20 million (US$22.6 million) convertible bonds issue of Sensorion, a clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat, and prevent inner ear diseases.